DocGo Inc. (NASDAQ: DCGO) Under Investigation for Possible False Statements and Insider Trading

Schubert Jonckheer & Kolbe LLP advises DocGo Inc. (NASDAQ: DCGO) investors that the firm is investigating potential legal claims relating to alleged false statements about the educational background of DocGo’s former CEO and the company’s business development efforts. Current shareholders are encouraged to contact us.

On March 28, 2025, Judge Katherine Polk Failla of the U.S. District Court for the Southern District of New York ruled that key claims in a securities fraud lawsuit against DocGo and its former CEO Anthony Capone could move forward. The lawsuit alleges that between April 2022 and September 2023, DocGo misled investors by falsely stating that Mr. Capone had a graduate degree in computer science and by misrepresenting DocGo’s efforts to enroll migrants in New York Medicaid programs and its business relationship with UnitedHealthcare. These statements allegedly caused DocGo’s stock to trade at artificially inflated prices. Judge Failla found that the complaint sufficiently alleged that the defendants made several “indisputably false” and misleading statements regarding these matters with an intent to defraud. During this period, company insiders sold approximately $4 million worth of DocGo stock. After the truth came out in September 2023 that Mr. Capone never attended graduate school, DocGo did not enroll anyone in Medicaid, and that UnitedHealthcare did not have a contract with DocGo in New York, DocGo’s stock price fell 25%.

We are investigating potential wrongdoing by DocGo’s directors and officers in connection with these allegations.

If you own stock in DocGo, you may have legal options. To learn more fill out the form below.